Delving into the Latest Updates on Inactivated SARS-CoV-2 vaccine (Vero cell) (Beijing Bio-Institute) with Synapse

The emergence of the SARS-CoV-2 virus worldwide led to the call for the development of effective and safe vaccines to contain the spread and effects of COVID-19. Using information from 40 publications, including clinical trials and observational studies from 2019 to 2024, this review assesses the effectiveness, safety, and limitations of four major vaccines: Sinopharm (BBIBP-CorV), Moderna (mRNA-1273), Pfizer-BioNTech (BNT162b2), and CoronaVac. Pfizer-BioNTech and Moderna's mRNA vaccines proved to be more effective than others; Moderna's vaccines showed an efficacy of 94.1 % against symptomatic infection, while Pfizer-BioNTech's vaccines showed an efficacy of up to 95 %, against severe diseases and hospitalization. These vaccinations, which included protection against Omicron and Delta variants, offered notable protection against serious illness, hospitalization, and mortality. Severe adverse events were rare while most adverse events were mild to moderate, such as headaches, fatigue, and localized reactions. In contrast, inactivated virus vaccines such as Sinopharm and CoronaVac with efficacies ranging from 50 to 79 % against symptomatic infection showed lower levels of effectiveness. In Phase 3 trial, Sinopharm showed 72.8 % efficacy, whereas CoronaVac demonstrated roughly 67 % efficacy in population against hospitalization and severe disease. Booster doses were required for adequate immunological response, especially against novel strains, as these vaccinations proved to be less effective in older populations. They showed considerable safety profiles, with mild side effects, but their low immunogenicity is concerning. This review emphasizes the importance of continuously evaluating vaccines in response to the evolving virus, essential for improving international immunization programs.

01 Apr 2025·Archives of Medical Research

Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases

Article

Author: Tomas-Grau, Rodrigo Hernán ; Pingitore, Esteban Vera ; Soliz-Santander, Silvana Estefanía ; Pera, Mariana ; Socias, Sergio Benjamín ; Leguizamón, María Lilia ; Cazorla, Silvia Inés ; Bertolaccini, María Constanza ; Barbaglia, Ana Lucía ; Ávila, César Luis ; Corbalan, Paula María ; Lucero, Luciana González ; Espasa, Gabriela Vanesa ; Ploper, Diego ; Maldonado-Galdeano, Carolina ; Sueldo, Héctor Raúl ; Bellomio, Verónica Inés ; Chehín, Rosana Nieves

BACKGROUNDPatients with autoimmune rheumatic diseases (ARD) are at increased risk of infection due to their impaired immune response, which also reduces vaccination efficacy. Although several studies have evaluated the serological response to SARS-CoV-2 mRNA-based vaccines in patients with ARD, limited information on immune responses to other vaccination platforms is available.AIMSThis observational prospective study aims to investigate the humoral immune response to different SARS-CoV-2 vaccines in patients with ARD.METHODSTotal 66 patients with ARD who were scheduled to receive any SARS-CoV-2 vaccine (Gam-COVID-Vac; AZD1222; BBIBP-CorV; mRNA-1273; BNT162b2 and Ad5-nCoV) were enrolled in the study. We analyzed the humoral immune response elicited against the spike receptor-binding-domain (RBD) of SARS-CoV-2 at 0 and 14 ± 2 d after the first vaccine dose and at 0 ± 1, 21-45, and 180 d after the second one. Titers were also measured in patients who received an additional dose of vaccine.RESULTSAfter the second dose of the vaccine, 70.5% experienced seroconversion. The type of vaccine affected serological responses. BBIBP-CorV resulted in lower seroconversion rates, while mixed vaccinations increased anti-RBD titers. Other factors impacting seroconversion were higher prednisone doses, biological therapy, and hypertension. Patients treated with Rituximab had the lowest seroconversion rate. Regression analysis revealed an 89.0% lower probability of seroconversion for BBIBP-CorV recipients and an 88.0% lower probability for those with hypertension. An additional dose increased seroconversion to 85.7%.CONCLUSIONSTwo-dose vaccination schemes exhibited a 70.5% seroconversion rate to the SARS-CoV-2 vaccine. An additional dose increased this rate to 85.0%. Reduced humoral immune responses were associated with BBIBP-CorV, prednisone higher doses, and biological therapy.

01 Feb 2025·Vaccine

Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection

Article

Author: Zhang, Yuqi ; Tu, Jing ; Yin, Yue ; Zhong, Yan ; Li, Xinjie ; Xu, Qiang ; Deng, Juan ; Shen, Tao ; Liang, Hua ; Yang, Yingxiang

The SARS-CoV-2 Omicron variant and its sublineages continue to circulate widely. Clinical outcomes with this variant differ among individuals, primarily influenced by host immunity. Previous studies have explored the relationship between immune responses and severe diseases in infected or convalescent patients. However, the impact of vaccine-induced immune responses on disease severity, especially in cases of mild infection following breakthrough infection, remains unclear. This is primarily due to the lack of assessment of immune status in vaccinated individuals before infection. In this study, we aimed to elucidate the causality between virus-specific cellular and humoral immune responses and the severity of symptoms in breakthrough infected patients from a long-term follow-up post-vaccination cohort. A questionnaire survey was conducted to collect general symptoms upon breakthrough infection with the Omicron variants. Plasma levels of specific antibodies (neutralizing antibodies, anti-S IgG, and anti-N IgG) and T cell responses induced by inactivated SARS-CoV-2 vaccine were evaluated. The findings revealed that individuals with milder symptoms, particularly lower peak fever temperatures, exhibited higher antibody levels and enhanced T cell activation and responses prior to infection. This suggests that cellular and humoral immunity induced by inactivated vaccines may provide protection against severe clinical symptoms following breakthrough infection.

100 Deals associated with Inactivated SARS-CoV-2 vaccine (Vero cell) (Beijing Bio-Institute)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
COVID-19	United Arab Emirates	Beijing Bio-Institute Biological Products Co. Ltd.	09 Dec 2020

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	Egypt	China National Biotec Group Co., Ltd.	16 Jul 2020
COVID-19	Preclinical	Jordan	China National Biotec Group Co., Ltd.	16 Jul 2020
COVID-19	Preclinical	Bahrain	China National Biotec Group Co., Ltd.	16 Jul 2020
Severe Acute Respiratory Syndrome	Preclinical	Egypt	China National Biotec Group Co., Ltd.	16 Jul 2020
Severe Acute Respiratory Syndrome	Preclinical	Bahrain	China National Biotec Group Co., Ltd.	16 Jul 2020
Severe Acute Respiratory Syndrome	Preclinical	Jordan	China National Biotec Group Co., Ltd.	16 Jul 2020
Severe Acute Respiratory Syndrome	Preclinical	United Arab Emirates	China National Biotec Group Co., Ltd.	16 Jul 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISTH2022	Not Applicable	Blood Coagulation Disorders	93	Sinopharm covid-19 Vaccine	qxxvzwefwm(vlcnyskcsk) = pkewkxrcrj zddxmbfiqx (vudjhwpkur )	-	09 Jul 2022
EHA2022	Not Applicable	Hemoglobinopathies	434	Sinopharm vaccine	cquyyyrihu(anodzbarfz) = qjmwhxldho hwzsshunww (hmmgyvabbm ) View more	-	10 Jun 2022
NCT05249816 (Pubmed \| Nat Commun) Manual	Phase 3	COVID-19	3,147,869	BBIBP-CorV	wiagzwgljy(qypwtrcsez) = kjldwgwwhq oldmocgbcw (edalnrrjrs, 82.2 - 89.0) View more	-	09 Jun 2022
ASCO2022	Not Applicable	Neoplasms	177	Pfizer-BioNTech vaccine	ovjhklmphs(zabehgudub) = 23 patients (13%) had confirmed COVID-19 infection (post AstraZeneca 1, Pfizer 13, Sinopharm 8, Sinovac 1) fkgdanabap (ywwdtgteaq ) View more	Positive	02 Jun 2022
ASCO2022	Not Applicable	Neoplasms	177	Sinopharm (Beijing) vaccine		Positive	02 Jun 2022
ChiCTR2000034780 \| NCT04510207 (CNBG2020003SQ, Pubmed) Manual	Phase 3	COVID-19	40,382	Inactivated COVID-19 Vaccine WIV04	(hmnbneuenf) = kiqetcbonm abtdzlnmhw (pbnhdcaqda ) View more	Positive	26 May 2021
	Phase 3	COVID-19	40,382	Inactivated COVID-19 Vaccine HB02	(hmnbneuenf) = bogiewgqda abtdzlnmhw (pbnhdcaqda ) View more	Positive	26 May 2021